Broken redirects
Jump to navigation
Jump to search
The following redirects link to non-existent pages:
Showing below up to 47 results in range #2,301 to #2,347.
- Data from ADHERE: BNP and Troponin are independent predictors of in-hospital mortality in patients with decompensated heart failure → Special:Badtitle/NS100:Data from ADHERE: BNP and Troponin are independent predictors of in-hospital mortality in patients with decompensated heart failure
- Defribillators: Systematic Review of ICDs for Adults with LV Systolic Dysfunction → Special:Badtitle/NS100:Defribillators: Systematic Review of ICDs for Adults with LV Systolic Dysfunction
- Diabetes Care Makes an "ADVANCE" with Better Blood Pressure Control → Special:Badtitle/NS100:Diabetes Care Makes an "ADVANCE" with Better Blood Pressure Control
- Diagnosing Heart Failure in the Emergency Department → Special:Badtitle/NS100:Diagnosing Heart Failure in the Emergency Department
- Door-to-Ballon Time less than 90 Minutes is Achievable and Sustainable: the Geisinger experience. August 12, 2007 → Special:Badtitle/NS100:Door-to-Ballon Time less than 90 Minutes is Achievable and Sustainable: the Geisinger experience. August 12, 2007
- Dronedarone (Multaq®) a Promising New Drug for the Management of Patients with Atrial Fibrillation or Flutter → Special:Badtitle/NS100:Dronedarone (Multaq®) a Promising New Drug for the Management of Patients with Atrial Fibrillation or Flutter
- Drug-Eluting Stents: Meta-analysis Demonstrates Superior Clinical Performance of Sirolimus-eluting Stents (SES) Over Bare-metal Stents (BMS) and Paclitaxel-eluting Stents (PES) → Special:Badtitle/NS100:Drug-Eluting Stents: Meta-analysis Demonstrates Superior Clinical Performance of Sirolimus-eluting Stents (SES) Over Bare-metal Stents (BMS) and Paclitaxel-eluting Stents (PES)
- Drug Eluting Stents Continue to Demonstrate Superiority over Bare Metal Stents in Reducing the Need for Repeat Revascularization → Special:Badtitle/NS100:Drug Eluting Stents Continue to Demonstrate Superiority over Bare Metal Stents in Reducing the Need for Repeat Revascularization
- Drug Eluting Stents are Associated with Reduced Mortality Compared with Bare Metal Stents → Special:Badtitle/NS100:Drug Eluting Stents are Associated with Reduced Mortality Compared with Bare Metal Stents
- Drug eluting stents: GRACE Analysis Shows Five Times Higher Mortality Rate Between Six Months and Two Years Among Patients Receivng DES → Special:Badtitle/NS100:Drug eluting stents: GRACE Analysis Shows Five Times Higher Mortality Rate Between Six Months and Two Years Among Patients Receivng DES
- Drug eluting stents are associated with reduced mortality in patients with myocardial infarction at two years → Special:Badtitle/NS100:Drug eluting stents are associated with reduced mortality in patients with myocardial infarction at two years
- Dual therapy better than monotherapy to treat hypertension in the ACCOMPLISH trial → Special:Badtitle/NS100:Dual therapy better than monotherapy to treat hypertension in the ACCOMPLISH trial
- Duke Research Teams Provide Insight into Small Vessels, Stored Blood, and Nitric Oxide → Special:Badtitle/NS100:Duke Research Teams Provide Insight into Small Vessels, Stored Blood, and Nitric Oxide
- Early Transfer of AMI Patients for PCI improves cardiovascular outcomes in the TRANSFER-AMI study → Special:Badtitle/NS100:Early Transfer of AMI Patients for PCI improves cardiovascular outcomes in the TRANSFER-AMI study
- Elevated Plasma Fibrinogen Levels among Diabetics and Increased BMI are Associated with Reduced Platelet Inhibition with Clopidogrel → Special:Badtitle/NS100:Elevated Plasma Fibrinogen Levels among Diabetics and Increased BMI are Associated with Reduced Platelet Inhibition with Clopidogrel
- Elevated microalbuminuria within the “normal-range” predicts mortality in patients with stable angina → Special:Badtitle/NS100:Elevated microalbuminuria within the “normal-range” predicts mortality in patients with stable angina
- Emergency Medical Services Remain Underutilized in STEMI Patients → Special:Badtitle/NS100:Emergency Medical Services Remain Underutilized in STEMI Patients
- Eptifibatide: Result of EVA-AMI Trial Released → Special:Badtitle/NS100:Eptifibatide: Result of EVA-AMI Trial Released
- Eptifibatide: Results of BRIEF-PCI Trial Released → Special:Badtitle/NS100:Eptifibatide: Results of BRIEF-PCI Trial Released
- Erectile dysfunction is associated with adverse cardiovascular events among diabetic patients → Special:Badtitle/NS100:Erectile dysfunction is associated with adverse cardiovascular events among diabetic patients
- Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience → Special:Badtitle/NS100:Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience
- Excel biodegradable stents are safe and effective: Results from the CREATE trial → Special:Badtitle/NS100:Excel biodegradable stents are safe and effective: Results from the CREATE trial
- ExoSeal® Vascular Closure Device is safe and effective → Special:Badtitle/NS100:ExoSeal® Vascular Closure Device is safe and effective
- Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection → Special:Badtitle/NS100:Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection
- Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI → Special:Badtitle/NS100:Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI
- Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis → Special:Badtitle/NS100:Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis
- F.I.R.E. Study Misses Primary Endpoint → Special:Badtitle/NS100:F.I.R.E. Study Misses Primary Endpoint
- FDA Advisors Under Review for the Potential of Financial Conflict. August 8, 2007 → Special:Badtitle/NS100:FDA Advisors Under Review for the Potential of Financial Conflict
- FDA Panel Recommends Approval of New DES → Special:Badtitle/NS100:FDA Panel Recommends Approval of New DES
- FDA Requires Stronger Heart Failure Warning for Avandia and Actos → Special:Badtitle/NS100:FDA Requires Stronger Heart Failure Warning for Avandia and Actos
- FFR-guided PCI Reduces Incidence of Clinical Events in Patients with Multi-Vessel Disease: Results of the FAME Study → Special:Badtitle/NS100:FFR-guided PCI Reduces Incidence of Clinical Events in Patients with Multi-Vessel Disease: Results of the FAME Study
- Facilitated PCI: No Benefit in FINESSE → Special:Badtitle/NS100:Facilitated PCI: No Benefit in FINESSE
- Feedback regulation of catecholamines levels through an enzyme called renalase → Special:Badtitle/NS100:Feedback regulation of catecholamines levels through an enzyme called renalase
- Fibrinolysis Followed by PCI Yielded Similar 1-Year Survival Rates to Primary PCI for STEMI in the French Registry → Special:Badtitle/NS100:Fibrinolysis Followed by PCI Yielded Similar 1-Year Survival Rates to Primary PCI for STEMI in the French Registry
- Fluvastatin XL therapy may prevent adverse cardiac outcomes in patients undergoing major vascular surgery: Results from the DECREASE III trial → Special:Badtitle/NS100:Fluvastatin XL therapy may prevent adverse cardiac outcomes in patients undergoing major vascular surgery: Results from the DECREASE III trial
- Function of an obesity-associated gene defined → Special:Badtitle/NS100:Function of an obesity-associated gene defined
- IMAGINE reported: early ACE inhibitor therapy in low risk CABG patients associated with worse early outcomes → Special:Badtitle/NS100:IMAGINE reported: early ACE inhibitor therapy in low risk CABG patients associated with worse early outcomes
- New data on possible pro-thrombotic effects of pioglitazone → Special:Badtitle/NS100:New data on possible pro-thrombotic effects of pioglitazone
- Special:Badtitle/NS100:No Connection Between Vaccines & Autism, Original Data Faked in Lancet → Special:Badtitle/NS100:No Connection Between Vaccines & Autism, Original Data Faked in ''Lancet''
- No cardiovascular risk associated with coffee consumption after MI → Special:Badtitle/NS100:No cardiovascular risk associated with coffee consumption after MI
- Optimal does of aspirin following ST-elevation myocardial infarction → Special:Badtitle/NS100:Optimal does of aspirin following ST-elevation myocardial infarction
- PCI not Cost Effective in the Occluded Artery Trial (OAT) → Special:Badtitle/NS100:PCI not Cost Effective in the Occluded Artery Trial (OAT)
- RACE study: Statewide System for Coronary Reperfusion for STEMI Patients Can Improve Quality of Care → Special:Badtitle/NS100:RACE study: Statewide System for Coronary Reperfusion for STEMI Patients Can Improve Quality of Care
- STEMI patients: the untreated, reperfusion eligible. August 8, 2007 → Special:Badtitle/NS100:STEMI patients: the untreated, reperfusion eligible.
- Today in Medicine: Study on the Effect of Obesity on Mortality Rates Following MI → Special:Badtitle/NS100:Study on the Effect of Obesity on Mortality Rates Following MI
- The ARMYDA 4 Trial → Special:Badtitle/NS100:The ARMYDA 4 Trial
- Unstable Angina (UA) and Non-ST-Elevation Myocardial Infarction (NSTEMI) ACC/AHA Guidelines Updated: August 7, 2007 → Special:Badtitle/NS100:Unstable Angina (UA) and Non-ST-Elevation Myocardial Infarction (NSTEMI) ACC/AHA Guidelines Updated